National Jewish Health
- Type
- Teaching hospital
- Where
- Denver, CO
- Medicare CCN
- 060107
- Received
- $6,951,516 in 335 records, 2021 ($2,653,329 general, $4,298,186 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: National Jewish Health Fuzzy (name and state)
- Business registration: National Jewish Health Fuzzy (name and state)
- Business registration: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Business registration: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Business registration: National Jewish Health Company Fuzzy (name and state)
- Business registration: NATIONAL JEWISH HEALTH, INC. Fuzzy (name and state)
- Nonprofit contractor: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Plan sponsor: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Federal award recipient: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Nonprofit: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Patent assignee: National Jewish Health Fuzzy (name and state)
- Trademark owner: National Jewish Health Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 70 | $2,653,329 |
| 2021 | Research payment | 265 | $4,298,186 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 265 | $4,298,186 |
| Grant | 23 | $2,322,697 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 10 | $186,974 |
| Charitable Contribution | 2 | $87,500 |
| Space rental or facility fees (teaching hospital only) | 15 | $30,000 |
| Royalty or License | 16 | $23,626 |
| Long term medical supply or device loan | 2 | $1,399 |
| Education | 1 | $1,000 |
| Debt forgiveness | 1 | $131 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $39,096 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $8,297 | Research payment | Cash or cash equivalent | NJHHumphriesCOPDCombinationCT | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $8,107 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2021 |
| 2021-12-31 | BioCryst Pharmaceuticals, Inc. | $7,021 | Research payment | Cash or cash equivalent | A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of BCX9930 in Sub | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $2,569 | Research payment | In-kind items and services | A Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inf | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $742 | Research payment | In-kind items and services | A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safet | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $131 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-31 | Merck Sharp & Dohme LLC | $60 | Research payment | In-kind items and services | Drug, RESPIRATORY | A 12-Week Study to Assess the Efficacy and Safety ofAF-219 MK-7264 in Subjects with Treatment RefractoryChronic Cough | 2021 |
| 2021-12-31 | Aimmune Therapeutics, Inc. | $21 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-12-29 | United Therapeutics Corporation | $5,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-28 | Aimmune Therapeutics, Inc. | $2,613 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-12-22 | United Therapeutics Corporation | $1,887 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RALINEPAG TO EVALUATE SAFETY AND EFFECTS ON EXERCISE CA | 2021 | |
| 2021-12-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | $60,473 | Research payment | Cash or cash equivalent | OFEV Drug, RESPIRATORY | US ECR 2021 00002556 | 2021 |
| 2021-12-21 | SANOFI US SERVICES INC. | $4,600 | Research payment | Cash or cash equivalent | REZUROCK Drug, Oncology | A Randomized Phase 2 Open Label Multicenter Study to Evaluate the Safety Tolerability and Activity of KD025 in Subjects | 2021 |
| 2021-12-20 | Spark Therapeutics, Inc. | $16,560 | Research payment | Cash or cash equivalent | 2021 | ||
| 2021-12-20 | GENZYME CORPORATION | $198 | Research payment | Cash or cash equivalent | An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ | 2021 | |
| 2021-12-17 | United Therapeutics Corporation | $2,764 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-12-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $64,016 | Research payment | Cash or cash equivalent | OFEV Drug, RESPIRATORY | CT scans using deep learning to assess lung fibros | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $7,020 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $5,814 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $2,578 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $1,165 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $710 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $710 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $300 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2021 |
| 2021-12-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-12-14 | Novartis Pharmaceuticals Corporation | $20,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-14 | Insmed, Inc. | $1,687 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy a | 2021 |
| 2021-12-13 | BioCryst Pharmaceuticals, Inc. | $385,219 | Research payment | Cash or cash equivalent | A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of BCX9930 in Sub | 2021 | |
| 2021-12-13 | Celgene Corporation | $70,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-13 | E.R. Squibb & Sons, L.L.C. | $70,000 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-12-13 | GENZYME CORPORATION | $15,120 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open-label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Pediatric Patients With Mod | 2021 |
| 2021-12-12 | Incyte Corporation | $562 | Research payment | Cash or cash equivalent | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2021 | |
| 2021-12-12 | Incyte Corporation | $562 | Research payment | Cash or cash equivalent | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2021 | |
| 2021-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,952 | Research payment | Cash or cash equivalent | Emphysema Progression Biomarker Study | 2021 | |
| 2021-12-08 | Genentech, Inc. | $1,114 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2021 |
| 2021-12-07 | AstraZeneca Pharmaceuticals LP | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2021 | |
| 2021-12-07 | Teva Pharmaceuticals USA, Inc. | $2,500 | Research payment | Cash or cash equivalent | Albuterol Sulfate Drug, Respiratory | CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Random | 2021 |
| 2021-12-07 | Teva Pharmaceuticals USA, Inc. | $1,279 | Research payment | Cash or cash equivalent | Albuterol Sulfate Drug, Respiratory | CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Random | 2021 |
| 2021-12-06 | SANOFI US SERVICES INC. | $1,400 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patient | 2021 |
| 2021-12-06 | Insmed, Inc. | $395 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $194 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $161 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $149 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $141 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $89 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $89 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $77 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $75 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $59 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $59 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $47 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $45 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $41 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $41 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $30 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $26 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-06 | Insmed, Inc. | $23 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-12-03 | Regeneron Pharmaceuticals, Inc. | $260,381 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | EFFECT OF DUPILUMAB (ANTI-IL4RA) ON THE HOST-MICROBE INTERFACE IN ATOPIC DERMATITIS | 2021 |
| 2021-12-03 | Genentech, Inc. | $5,487 | Research payment | Cash or cash equivalent | Xolair Biological, Immunology | USING OBJECTIVE PATIENT CENTRIC MEASURES TO SHOW IMPACT OF OMALIZUMAB ON ASTHMA IMPROVEMENT | 2021 |
| 2021-12-02 | Regeneron Pharmaceuticals, Inc. | $2,667 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-12-01 | AstraZeneca Pharmaceuticals LP | $158,407 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-01 | SANOFI US SERVICES INC. | $61,947 | Research payment | Cash or cash equivalent | REGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis | 2021 | |
| 2021-12-01 | AstraZeneca Pharmaceuticals LP | $20,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-01 | Boehringer Ingelheim International GmbH | $37 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2021 |
| 2021-11-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $43,436 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-11-24 | Merck Sharp & Dohme LLC | $43,964 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2021 |
| 2021-11-24 | Alexion Pharmaceuticals, Inc. | $36,419 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-11-24 | Bio-Rad Laboratories, Inc. | $59 | Royalty or License | Cash or cash equivalent | Antibody Device, Market Research | 2021 | |
| 2021-11-23 | Mylan Specialty L.P. | $17,500 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-11-23 | United Therapeutics Corporation | $3,148 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RALINEPAG TO EVALUATE SAFETY AND EFFECTS ON EXERCISE CA | 2021 | |
| 2021-11-23 | United Therapeutics Corporation | $1,077 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-11-23 | Incyte Corporation | $260 | Research payment | Cash or cash equivalent | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2021 | |
| 2021-11-23 | Incyte Corporation | $260 | Research payment | Cash or cash equivalent | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2021 | |
| 2021-11-22 | GENZYME CORPORATION | $15,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-11-18 | Alexion Pharmaceuticals, Inc. | $42,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-11-18 | Alexion Pharmaceuticals, Inc. | $10,771 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-11-18 | Becton, Dickinson and Company | $187 | Royalty or License | Cash or cash equivalent | BD OptiBuild Device, Cell Analysis | 2021 | |
| 2021-11-15 | PFIZER INC. | $120,323 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-11-15 | GENZYME CORPORATION | $595 | Research payment | Cash or cash equivalent | An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ | 2021 | |
| 2021-11-11 | Regeneron Pharmaceuticals, Inc. | $392 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-11-05 | BioCryst Pharmaceuticals, Inc. | $4,680 | Research payment | Cash or cash equivalent | A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of BCX9930 in Sub | 2021 | |
| 2021-11-05 | Genentech, Inc. | $2,500 | Research payment | Cash or cash equivalent | Xolair Biological, Immunology | USING OBJECTIVE PATIENT CENTRIC MEASURES TO SHOW IMPACT OF OMALIZUMAB ON ASTHMA IMPROVEMENT | 2021 |
| 2021-11-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21,726 | Research payment | Cash or cash equivalent | OFEV Drug, RESPIRATORY | ILD in in Early Rheumatoid Arthritis | 2021 |
| 2021-11-03 | Regeneron Pharmaceuticals, Inc. | $785 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-11-02 | GENZYME CORPORATION | $165,630 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open-label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Pediatric Patients With Mod | 2021 |
| 2021-11-01 | AstraZeneca Pharmaceuticals LP | $114,987 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-11-01 | SANOFI US SERVICES INC. | $61,947 | Research payment | Cash or cash equivalent | REGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis | 2021 | |
| 2021-11-01 | Boehringer Ingelheim International GmbH | $37 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2021 |
| 2021-10-28 | VERTEX PHARMACEUTICALS INCORPORATED | $7,454 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy i | 2021 | |
| 2021-10-28 | Janssen Research & Development, LLC | $5,359 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2021 | |
| 2021-10-28 | Janssen Research & Development, LLC | $5,359 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2021 | |
| 2021-10-28 | Insmed, Inc. | $1,833 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reporte | 2021 |
| 2021-10-28 | Insmed, Inc. | $1,662 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reporte | 2021 |
| 2021-10-26 | Beckman Coulter, Inc. | $10,000 | Royalty or License | Cash or cash equivalent | 2021 | ||
| 2021-10-26 | Genentech, Inc. | $2,103 | Research payment | Cash or cash equivalent | Xolair Biological, Immunology | MEASURING RESPONSES TO XOLAIR OMALIZUMAB USING MHEALTH TECHNOLOGIES | 2021 |
| 2021-10-25 | Eli Lilly and Company | $10,000 | Research payment | Cash or cash equivalent | 2021 | ||
| 2021-10-20 | United Therapeutics Corporation | $626 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RALINEPAG TO EVALUATE SAFETY AND EFFECTS ON EXERCISE CA | 2021 | |
| 2021-10-19 | Teva Pharmaceuticals USA, Inc. | $12,833 | Research payment | Cash or cash equivalent | Albuterol Sulfate Drug, Respiratory | CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Random | 2021 |
| 2021-10-19 | Roche Products Limited | $2,655 | Research payment | Cash or cash equivalent | Esbriet Biological, Immunology | TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | 2021 |
| 2021-10-18 | GENZYME CORPORATION | $1,170 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S | 2021 |
| 2021-10-15 | United Therapeutics Corporation | $8,550 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-10-13 | Teva Pharmaceuticals USA, Inc. | $4,622 | Research payment | Cash or cash equivalent | Albuterol Sulfate Drug, Respiratory | CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Random | 2021 |
| 2021-10-13 | Regeneron Pharmaceuticals, Inc. | $280 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-10-12 | AstraZeneca Pharmaceuticals LP | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FASENRA Biological, Respiratory | 2021 | |
| 2021-10-12 | Amgen Inc. | $1,250 | Royalty or License | Cash or cash equivalent | 2021 | ||
| 2021-10-07 | Regeneron Pharmaceuticals, Inc. | $913 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-10-05 | Roche Products Limited | $12,833 | Research payment | Cash or cash equivalent | Esbriet Biological, Immunology | TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | 2021 |
| 2021-10-05 | Insmed, Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-10-05 | Insmed, Inc. | $52 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2021 | |
| 2021-10-04 | Spark Therapeutics, Inc. | $10,235 | Research payment | Cash or cash equivalent | 2021 | ||
| 2021-10-01 | SANOFI US SERVICES INC. | $61,947 | Research payment | Cash or cash equivalent | REGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis | 2021 | |
| 2021-10-01 | VERTEX PHARMACEUTICALS INCORPORATED | $653 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy i | 2021 | |
| 2021-10-01 | Boehringer Ingelheim International GmbH | $37 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2021 |
| 2021-09-30 | Regeneron Pharmaceuticals, Inc. | $940 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-09-30 | Insmed, Inc. | $76 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reporte | 2021 |
| 2021-09-28 | Janssen Research & Development, LLC | $67,000 | Research payment | Cash or cash equivalent | Non Clinical Agreement between Janssen Research & Development, LLC, and National Jewish Health | 2021 | |
| 2021-09-27 | GENZYME CORPORATION | $220,670 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S | 2021 |
| 2021-09-27 | United Therapeutics Corporation | $6,923 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RALINEPAG TO EVALUATE SAFETY AND EFFECTS ON EXERCISE CA | 2021 | |
| 2021-09-22 | United Therapeutics Corporation | $3,188 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-09-21 | Aimmune Therapeutics, Inc. | $2,543 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-09-20 | GENZYME CORPORATION | $2,500 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S | 2021 |
| 2021-09-20 | GENZYME CORPORATION | $1,242 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S | 2021 |
| 2021-09-16 | Regeneron Pharmaceuticals, Inc. | $1,545 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-09-09 | Regeneron Pharmaceuticals, Inc. | $112 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-09-02 | SANOFI US SERVICES INC. | $61,947 | Research payment | Cash or cash equivalent | REGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis | 2021 | |
| 2021-09-02 | Sage Therapeutics, LLC | $15,498 | Research payment | Cash or cash equivalent | ZULRESSO Drug, PSYCHIATRYPSYCHOLOGY | A STUDY OF BREXANOLONE FOR ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 | 2021 |
| 2021-09-02 | Regeneron Pharmaceuticals, Inc. | $1,221 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-09-02 | SANOFI US SERVICES INC. | $600 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe A | 2021 |
| 2021-09-01 | AstraZeneca Pharmaceuticals LP | $157,602 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-09-01 | AstraZeneca Pharmaceuticals LP | $114,988 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-09-01 | Boehringer Ingelheim International GmbH | $37 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2021 |
| 2021-08-26 | Amgen Inc. | $29,780 | Research payment | Cash or cash equivalent | In-vitro Testing of Two Compounds on Human Samples | 2021 | |
| 2021-08-26 | Insmed, Inc. | $7,000 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy a | 2021 |
| 2021-08-26 | Insmed, Inc. | $7,000 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reporte | 2021 |
| 2021-08-26 | Regeneron Pharmaceuticals, Inc. | $2,062 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-08-26 | Insmed, Inc. | $2,000 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reporte | 2021 |
| 2021-08-26 | Insmed, Inc. | $2,000 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy a | 2021 |
| 2021-08-26 | Insmed, Inc. | $1,500 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy a | 2021 |
| 2021-08-26 | Insmed, Inc. | $1,500 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reporte | 2021 |
| 2021-08-26 | Insmed, Inc. | $1,333 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reporte | 2021 |
| 2021-08-26 | Insmed, Inc. | $1,333 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy a | 2021 |
| 2021-08-26 | Insmed, Inc. | $950 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy a | 2021 |
| 2021-08-26 | Insmed, Inc. | $950 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reporte | 2021 |
| 2021-08-26 | Insmed, Inc. | $500 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reporte | 2021 |
| 2021-08-26 | Insmed, Inc. | $500 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy a | 2021 |
| 2021-08-24 | Becton, Dickinson and Company | $304 | Royalty or License | Cash or cash equivalent | BD Pharmingen Device, Cell Analysis | 2021 | |
| 2021-08-24 | Becton, Dickinson and Company | $30 | Royalty or License | Cash or cash equivalent | BD Pharmingen Device, Cell Analysis | 2021 | |
| 2021-08-23 | GENZYME CORPORATION | $180,000 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S | 2021 |
| 2021-08-16 | SANOFI US SERVICES INC. | $23,085 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patient | 2021 |
| 2021-08-16 | GENZYME CORPORATION | $588 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S | 2021 |
| 2021-08-13 | Bio-Rad Laboratories, Inc. | $117 | Royalty or License | Cash or cash equivalent | Antibody Device, Market Research | 2021 | |
| 2021-08-12 | Regeneron Pharmaceuticals, Inc. | $255 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-08-10 | Teva Pharmaceuticals USA, Inc. | $3,456 | Research payment | Cash or cash equivalent | Albuterol Sulfate Drug, Respiratory | CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Random | 2021 |
| 2021-08-06 | Insmed, Inc. | $1,833 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reporte | 2021 |
| 2021-08-06 | Insmed, Inc. | $1,247 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reporte | 2021 |
| 2021-08-05 | Regeneron Pharmaceuticals, Inc. | $1,165 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-08-01 | Boehringer Ingelheim International GmbH | $37 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2021 |
| 2021-07-26 | GENZYME CORPORATION | $595 | Research payment | Cash or cash equivalent | An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ | 2021 | |
| 2021-07-22 | Regeneron Pharmaceuticals, Inc. | $499 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-22 | Regeneron Pharmaceuticals, Inc. | $499 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-22 | Regeneron Pharmaceuticals, Inc. | $389 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-22 | Regeneron Pharmaceuticals, Inc. | $389 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-22 | Regeneron Pharmaceuticals, Inc. | $346 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-22 | Regeneron Pharmaceuticals, Inc. | $333 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-22 | Regeneron Pharmaceuticals, Inc. | $333 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-22 | Regeneron Pharmaceuticals, Inc. | $280 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-22 | Regeneron Pharmaceuticals, Inc. | $275 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-22 | Regeneron Pharmaceuticals, Inc. | $259 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-22 | Regeneron Pharmaceuticals, Inc. | $259 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-21 | LEO Pharma AS | $16,500 | Research payment | Cash or cash equivalent | TRALOKINUMAB: CONFIRMATORY TRIAL IN ADOLESCENTS | 2021 | |
| 2021-07-19 | Janssen Research & Development, LLC | $27,612 | Research payment | Cash or cash equivalent | National Jewish Health Chronic Respiratory Disease Associated Pulmonary Hypertension Registry The Cardinal PH Registry | 2021 | |
| 2021-07-19 | Janssen Research & Development, LLC | $27,612 | Research payment | Cash or cash equivalent | National Jewish Health Chronic Respiratory Disease Associated Pulmonary Hypertension Registry The Cardinal PH Registry | 2021 | |
| 2021-07-15 | Regeneron Pharmaceuticals, Inc. | $2,515 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-14 | United Therapeutics Corporation | $1,500 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-07-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,248 | Research payment | Cash or cash equivalent | US SAG 2020 00002458 American Lung Association L | 2021 | |
| 2021-07-02 | Incyte Corporation | $6,226 | Research payment | Cash or cash equivalent | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2021 | |
| 2021-07-01 | Regeneron Pharmaceuticals, Inc. | $266 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-01 | Regeneron Pharmaceuticals, Inc. | $244 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-07-01 | Boehringer Ingelheim International GmbH | $37 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2021 |
| 2021-06-30 | ABBVIE INC. | $8,833 | Research payment | Cash or cash equivalent | A Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for | 2021 | |
| 2021-06-27 | Genentech, Inc. | $223 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2021 |
| 2021-06-25 | Genentech, Inc. | $4,206 | Research payment | Cash or cash equivalent | Xolair Biological, Immunology | MEASURING RESPONSES TO XOLAIR OMALIZUMAB USING MHEALTH TECHNOLOGIES | 2021 |
| 2021-06-24 | Insmed, Inc. | $1,833 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reporte | 2021 |
| 2021-06-23 | Genentech, Inc. | $7,014 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2021 |
| 2021-06-23 | Becton, Dickinson and Company | $5,000 | Royalty or License | Cash or cash equivalent | 2021 | ||
| 2021-06-23 | Regeneron Pharmaceuticals, Inc. | $1,626 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-06-21 | GENZYME CORPORATION | $397,206 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S | 2021 |
| 2021-06-21 | United Therapeutics Corporation | $2,764 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-06-21 | GENZYME CORPORATION | $1,190 | Research payment | Cash or cash equivalent | An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ | 2021 | |
| 2021-06-11 | Incyte Corporation | $2,605 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2021 | |
| 2021-06-09 | Bio-Rad Laboratories, Inc. | $50 | Royalty or License | Cash or cash equivalent | Antibody Device, Market Research | 2021 | |
| 2021-06-08 | Aimmune Therapeutics, Inc. | $2,706 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-04 | BioMarin Pharmaceutical Inc. | $10,005 | Research payment | Cash or cash equivalent | Palynziq Drug, PKU | An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dose | 2021 |
| 2021-06-04 | United Therapeutics Corporation | $1,195 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-06-02 | GENZYME CORPORATION | $264,804 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S | 2021 |
| 2021-06-02 | E.R. Squibb & Sons, L.L.C. | $51,473 | Research payment | Cash or cash equivalent | Phase II Pulmonary Fibrosis Add-On and Treatment Nave | 2021 | |
| 2021-06-02 | GENZYME CORPORATION | $10,388 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S | 2021 |
| 2021-06-01 | Incyte Corporation | $1,766 | Research payment | Cash or cash equivalent | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2021 |
The latest 200 records of 335.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Denver, CO, county Denver County, CO, state Colorado; placed by its city name.
| Measure | Place (city or town) Denver, CO | County Denver County, CO | State Colorado |
|---|---|---|---|
| Population B01003 | 718,877 | 718,877 | 5,862,189 |
| Population, 2020 census P1 | 715,522 | 715,522 | 5,773,714 |
| Median age B01002 | 35.3 | 35.3 | 37.7 |
| Under 18 B01001 | 18.0% | 18.0% | 21.0% |
| 65 and over B01001 | 12.5% | 12.5% | 15.6% |
| Households B11001 | 335,428 | 335,428 | 2,374,218 |
| Foreign born B05002 | 14.5% | 14.5% | 9.8% |
| Median household income B19013 | $94,718 | $94,718 | $95,470 |
| Median family income B19113 | $124,743 | $124,743 | $119,139 |
| Per capita income B19301 | $64,163 | $64,163 | $52,636 |
| Poverty rate B17001 | 11.2% | 11.2% | 9.4% |
| Unemployment rate B23025 | 4.9% | 4.9% | 4.6% |
| Civilian labor force B23025 | 447,681 | 447,681 | 3,235,476 |
| Mean commute (minutes) B08013 | 24.9 | 24.9 | 25.2 |
| Bachelor's degree or higher B15003 | 56.5% | 56.5% | 45.7% |
| Housing units B25001 | 359,581 | 359,581 | 2,589,053 |
| Owner-occupied B25003 | 48.8% | 48.8% | 66.2% |
| Renters B25003 | 51.2% | 51.2% | 33.8% |
| Median home value B25077 | $616,000 | $616,000 | $539,400 |
| Median gross rent B25064 | $1,831 | $1,831 | $1,761 |
| White, not Hispanic B03002 | 54.0% | 54.0% | 64.8% |
| Black B03002 | 8.6% | 8.6% | 3.8% |
| Hispanic or Latino B03002 | 28.0% | 28.0% | 22.5% |
| Asian B03002 | 3.6% | 3.6% | 3.2% |
| American Indian and Alaska Native B03002 | 0.3% | 0.3% | 0.4% |
Economy now FRED unemployment 4.1% in Sep 2026 (3.8% a year earlier); per capita personal income $86,342 in 2025, up 34% in five years (+7.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Denver, CO.
Comments